The Pradaxa bleeding risk has been well documented throughout the United States, through numerous injury reports and a handful of deaths.

While a bleeding antidote was recently developed by Boehringer Ingelheim, the overall Pradaxa bleeding risk is still present.

Furthermore, many patients allege these internal bleeding complications were not properly addressed until litigation proceedings began against the company.

Pradaxa was approved by the FDA in 2010, and is manufactured by Boehringer Ingelheim.

This medication was widely successful for the treatment purpose of blood thinning. After experiencing this market success, other pharmaceutical companies followed suit with the release of Xarelto and Eliquis in 2011 and 2012 respectively.

Most popularly, Pradaxa is prescribed to patients suffering from atrial fibrillation and are at high risk for stroke. Pradaxa works by inhibiting the body’s clotting mechanism, which is meant to improve blood circulation.

However this treatment mechanism has been allegedly inducing the Pradaxa bleeding risk, as the body is unable to recover from minor internal bleeding events. Injuries the body could normally recover from become life threatening complications, as emergency intervention is needed to stop the bleeding.

Even though Pradaxa bleeding antidote Praxbind was recently approved in 2015, patients can still only receive the reversal agent from hospitals. America’s original blood thinner, Warfarin, is currently the only anticoagulant with a readily available reversal agent.

Overview of Pradaxa Bleeding Risk

Pradaxa had quickly gained popularity for its convenience, as it was prescribed in one dose and did not require frequent dose adjustments from doctors. However, patients complained that the warning label did not adequately describe the severity of Pradaxa bleeding risk.

In 2011, the FDA had received 817 reports of Pradaxa bleeding complications with thousands more submitted in other databases. In total, there were 3,781 Pradaxa bleeding injuries with over 500 of them being fatal.

According to a recent study by the University of Pittsburgh, approximately 9 percent of Pradaxa patients had experienced major internal bleeding complications compared to 6 percent of Warfarin patients.

Even though Pradaxa bleeding risk can be potentially fatal, Boehringer Ingelheim allegedly failed to warn patients against them.

Ever since Pradaxa bleeding risk became well known to the patient population and medical community, there have been numerous Pradaxa lawsuits filed. Pradaxa patients who allegedly experienced internal bleeding complications should contact a specialized lawyer to determine eligibility for a Pradaxa lawsuit.